Filing Details

Accession Number:
0001735276-23-000006
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-03 17:45:42
Reporting Period:
2023-02-01
Accepted Time:
2023-02-03 17:45:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1849458 Tolga Tanguler 675 West Kendall Street
Henri A. Termeer Square
Cambridge MA 02142
Evp, Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-01 5,025 $0.00 5,025 No 4 M Direct
Common Stock Disposition 2023-02-02 73 $223.97 4,952 No 4 S Direct
Common Stock Disposition 2023-02-02 963 $225.80 3,989 No 4 S Direct
Common Stock Disposition 2023-02-02 561 $226.62 3,428 No 4 S Direct
Common Stock Disposition 2023-02-02 4 $227.38 3,424 No 4 S Direct
Common Stock Disposition 2023-02-03 128 $227.68 3,296 No 4 S Direct
Common Stock Disposition 2023-02-03 185 $230.20 3,111 No 4 S Direct
Common Stock Disposition 2023-02-03 865 $231.35 2,246 No 4 S Direct
Common Stock Disposition 2023-02-03 1,293 $232.53 953 No 4 S Direct
Common Stock Disposition 2023-02-03 953 $233.31 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-02-01 5,025 $0.00 5,025 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
Footnotes
  1. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
  2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.42 to $224.25. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $225.21 to $226.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.23 to $227.12. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.
  6. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.63 to $228.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  7. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.87 to $230.62. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  8. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.90 to $231.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  9. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.94 to $232.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  10. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.02 to $233.81. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  11. Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
  12. On February 1, 2021 the reporting person received 10,051 restricted stock units, one-half of which vested on the first anniversary of the grant date, and one-half of which vested on the second anniversary of the grant date (February 1, 2023).